ARQTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Arcutis Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$31.89+3.07 (+10.65%)
Close on Oct 19, 2026
- Market cap
- $4.33B
- P/E (TTM)
- 145.0
- Dividend yield
- –
Arcutis Biotherapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| ZORYVE foam | $181.89M | $71.54M | $0 | $0 | – | – | 48.4% | +154.3% |
| ZORYVE cream 0.3% | $121.00M | $85.08M | $29.19M | $3.69M | – | – | 32.2% | +42.2% |
| ZORYVE cream 0.15% | $68.27M | $9.92M | $0 | $0 | – | – | 18.2% | +588.2% |
| ZORYVE cream 0.05% | $911.00K | $0 | $0 | – | – | – | 0.2% | – |
| Product revenue, net | – | – | $29.19M | $3.69M | $0 | $0 | – | – |
| Other revenue | – | – | $30.42M | $0 | $0 | – | – | – |
By region
From the segment and revenue-disaggregation notes of Arcutis Biotherapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.